Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,523 shares of the medical equipment provider’s stock after purchasing an additional 257 shares during the quarter. New York Life Investment Management LLC’s holdings in Hologic were worth $2,752,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. McGlone Suttner Wealth Management Inc. acquired a new stake in Hologic in the 4th quarter valued at about $27,000. Venturi Wealth Management LLC acquired a new stake in shares of Hologic in the 3rd quarter worth $29,000. NBC Securities Inc. acquired a new stake in shares of Hologic in the 3rd quarter worth $33,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 155 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its position in shares of Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 227 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Trading Up 0.8 %

HOLX opened at $76.54 on Monday. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $86.74. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $76.13 and a 200-day simple moving average of $73.05. The firm has a market cap of $17.97 billion, a P/E ratio of 39.05, a P/E/G ratio of 2.59 and a beta of 1.01.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 18.81% and a net margin of 11.78%. Hologic’s revenue for the quarter was down .8% on a year-over-year basis. During the same period last year, the business posted $1.06 EPS. On average, equities analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on HOLX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Friday. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday. Raymond James upped their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Evercore ISI raised their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Finally, JPMorgan Chase & Co. upped their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research note on Friday. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $84.56.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.